Samsung Bioepis and Sandoz expand their biosimilar partnership to cover vedolizumab SB36 and four early-stage candidates. What this means for the IBD biologics market.
AbbVie reports positive Phase 3 AFFIRM trial results for risankizumab subcutaneous induction in Crohn’s disease. Discover what the findings mean for treatment.
Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.
Discover how NImmune Biopharma’s NIM-1324 Phase 2 program could reshape inflammatory bowel disease treatment beyond biologics and JAK inhibitors.
Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.
New ECCO 2026 data explore whether subcutaneous infliximab can reliably recapture disease control after treatment interruption. Read the analysis.
WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and clinical manufacturing of SND006, a novel bispecific antibody targeting inflammatory bowel disease and other autoimmune conditions. The agreement will see Sinorda Biomedicine utilize WuXi Biologics’ CRDMO capabilities to support preclinical development, IND-enabling activities, and global clinical supply for SND006, […]
Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.
Find out how PhaseV’s AI-powered ClinOps Optimizer is changing IBD trial site selection with causal ML and real-time analytics. Read the full analysis.
A mouse study suggests young microbiota can rejuvenate aging gut tissue. Find out what this could mean for regenerative GI therapies and IBD care.